跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

C0621

Sigma-Aldrich

CI−994

≥98% (HPLC), powder

别名:

4-乙酰氨基-N-(2′-氨基苯基)苯甲酰胺, 乙酰地那林, 醋地那林

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C15H15N3O2
CAS号:
112522-64-2
分子量:
269.30
MDL编号:
MFCD00866266
UNSPSC代码:
12352200
PubChem化学物质编号:
329774808
NACRES:
NA.77

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

off-white

溶解性

DMSO: >10 mg/mL

储存温度

room temp

SMILES字符串

CC(=O)Nc1ccc(cc1)C(=O)Nc2ccccc2N

InChI

1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)

InChI key

VAZAPHZUAVEOMC-UHFFFAOYSA-N

基因信息

human ... HDAC1(3065) , HDAC10(83933) , HDAC11(79885) , HDAC2(3066) , HDAC3(8841) , HDAC4(9759) , HDAC5(10014) , HDAC6(10013) , HDAC7(51564) , HDAC8(55869) , HDAC9(9734)

应用

CI-994 已用于：
  • 作为组蛋白脱乙酰基酶（HDAC）抑制剂，用于处理 SUM229 和 DT22 细胞，以研究其作用
  • 作为 HDAC 抑制剂，用在 SPEL 细胞中进行筛选
  • 研究其对人类骨髓和红系祖细胞的影响

生化/生理作用

Ci-994 是原始化合物地那林（PD 104 208）的乙酰化衍生物形式。它是一种口服细胞抑制药物，对白血病细胞和正常干细胞的活性差异显著。它用于特定肿瘤的联合治疗，包括非小细胞肺癌、胰腺癌、乳腺癌和结直肠癌。它起组蛋白脱乙酰基酶抑制剂的作用。CI-994 在细胞周期的 G1-S 期阻断细胞。16 kDa 的磷蛋白被限制在核区中。16-kDa 核磷蛋白的丢失似乎是 CI-994 处理的直接效果，并且对该磷蛋白的抑制可能在 CI-994 的作用机理中起关键作用。
口服 HDAC 抑制剂；CI-994 在细胞周期的 G1-S 期阻断细胞。

特点和优势

这种化合物是基因调控研究的特色产品。点击此处发现更多特色基因调控产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H319

危险分类

Eye Irrit. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000208192
0000208192
0000139827
0000139828
0000138977

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

CoREST Complex-Selective Histone Deacetylase Inhibitors Show Prosynaptic Effects and an Improved Safety Profile To Enable Treatment of Synaptopathies
Fuller NO, et al.
ACS Chemical Neuroscience (2019)
Suxiang Zhang et al.
Cell death & disease, 9(5), 460-460 (2018-04-28)
Spinal cord injury (SCI) induces severe and long-lasting neurological disability. Accumulating evidence has suggested that histone deacetylase (HDAC) inhibitors exert neuroprotective effects against various insults and deficits in the central nervous system. In the present study, we assessed the effect
H M el-Beltagi et al.
Leukemia, 7(11), 1795-1800 (1993-11-01)
The efficacy of acetyldinaline [4-acetylamino-N-(2'-aminophenyl)-benzamide] for eradication of minimal residual disease (MRD), which is left after bone marrow transplantation, and the risk of a bone marrow graft being jeopardized by this treatment was studied in the Brown Norway rat acute
S D Undevia et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 15(11), 1705-1711 (2004-11-03)
This study was conducted to determine the toxicity profile, maximum tolerated dose (MTD) and pharmacokinetics of the putative histone deacetylase inhibitor CI-994 in combination with capecitabine. Fifty-four patients were treated according to three different dosing schemes in which the capecitabine
Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi?s sarcoma-associated herpesvirus
Osawa M, et al.
Infectious Agents and Cancer, 11(1), 37-37 (2016)
查看所有相关文献

商品

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门